Clinical Trial News and Research

RSS

FDA approves Abbott's XIENCE PRIME Everolimus Eluting Coronary Stent System

Abbott today announced it has received U.S. Food and Drug Administration (FDA) approval for the next-generation XIENCE PRIME Everolimus Eluting Coronary Stent System for the treatment of coronary artery disease.

2 Nov 2011

Rigel reports net loss of $17.9 million for third quarter 2011

Rigel Pharmaceuticals, Inc. today reported financial results for the third quarter and nine months ended September 30, 2011.

1 Nov 2011

Multi-centre phase II trial for new brain tumor surgical technique starts in the UK

A multi-centre phase II clinical trial for a pioneering new surgical technique has started in the UK, jointly funded by Samantha Dickson Brain Tumour Trust and Cancer Research UK.

1 Nov 2011

Non-invasive rtACS treatment can reduce partial blindness

It has long been thought that blindness after brain lesions is irreversible and that damage to the optic nerves leads to permanent impairments in everyday activities such as reading, driving, and spatial orientation. A new study published in Elsevier's Brain Stimulation suggests that treating such patients with low levels of non-invasive, repetitive, transorbital alternating current stimulation (rtACS) for 10 days significantly reduces visual impairment and markedly improves vision-related quality of life.

1 Nov 2011

Focused training increases physician's ability to find potentially precancerous polyps

Just two extra hours of focused training significantly increased the ability of physicians to find potentially precancerous polyps, known as adenomas, in the colon, according to researchers at Mayo Clinic in Florida. These findings suggest that new methods to educate endoscopists, the physicians who examine the colon, could increase colorectal cancer detection rates and potentially reduce cancer deaths.

31 Oct 2011

Vegenics receives IND approval from FDA for VGX-100 Phase I study in late stage cancers

Circadian Technologies Limited announces that its 100% owned subsidiary, Vegenics Pty Ltd, has received approval for its investigational new drug application from the U.S. Food and Drug Administration to initiate clinical trials of VGX-100.

31 Oct 2011

Positive initial results from CytRx's INNO-206 Phase 1b/2 clinical trial for advanced solid tumors

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced favorable response and safety indications from a group of patients with advanced solid tumors (principally soft tissue sarcomas) in the Company's ongoing Phase 1b/2 clinical trial with INNO-206, its tumor-targeting conjugate of the commonly used chemotherapeutic agent doxorubicin.

31 Oct 2011

Fierce Vaccines highlights Inovio's VGX-3100 as one of 10 Promising Therapeutic Vaccines

Inovio Pharmaceuticals, Inc., which is advancing synthetic vaccines to fight cancers and infectious diseases, announced today that VGX-3100, its investigational SynCon vaccine for treating cervical dysplasia and cancer caused by human papillomavirus, was highlighted by Fierce Vaccines as one of 10 Promising Therapeutic Vaccines.

31 Oct 2011

Hercules Pharma granted rights to license 22nd Century's X-22 smoking cessation aid

22nd Century Group, Inc., a company focused on smoking cessation and tobacco harm reduction products, announced today that the company licensed Hercules Pharmaceuticals LLC, its wholly-owned pharmaceutical subsidiary, exclusive worldwide rights to X-22.

31 Oct 2011

Medtronic’s atrial fibrillation device fails to impress safety panel

The US health advisers rejected a Medtronic Inc. device for treating atrial fibrillation, a heart rhythm disorder that is a major cause of stroke, citing risks to safety. The panel voted 8-2 that risks of device outweigh benefits of the Medtronic Cardiac Ablation System especially given the high number of strokes among patients who got the device during clinical trials.

From Medtronic 30 Oct 2011

Ovarian cancer patients with many folate receptors benefit from new therapy

A new strategy that takes advantage of ovarian cancer's reliance on folate appears to give relapse patients extra months of life with few side effects, researchers say.

29 Oct 2011

Some experts question early release of RTS,S malaria vaccine trial data

Nature News reports on last week's announcement of preliminary results from a large clinical trial testing the efficacy of GlaxoSmithKline's (GSK) RTS,S malaria vaccine, writing that while media coverage of the announcement touted it as a "big breakthrough in the long campaign to create a malaria vaccine," "several leading vaccine researchers, who are critical of the unusual decision to publish partial trial data, argue that the results raise questions about whether the RTS,S/AS01 candidate vaccine can actually win approval."

29 Oct 2011

More than 50,000 patients at high risk of SCA have been prescribed ZOLL's LifeVest

ZOLL Medical Corporation, a manufacturer of medical devices and related software solutions, announced today that more than 50,000 patients at high risk of sudden cardiac arrest (SCA) have been prescribed the LifeVest Wearable Defibrillator.

29 Oct 2011

FDA approves Medtronic's LGS IDE for clinical trial to treat Type 1 diabetes

In our continued commitment to develop an artificial pancreas, Medtronic, Inc. today announced U.S. Food and Drug Administration (FDA) approval of its Investigational Device Exemption (IDE) to conduct a pivotal in-home clinical trial protocol for the ASPIRE study of the MiniMed Paradigm System featuring Low Glucose Suspend (LGS) automation.

From Medtronic 29 Oct 2011

Merck third quarter global sales increase 8% to $12.0 billion

Merck, known as MSD outside the United States and Canada, today announced financial results for the third quarter of 2011.

29 Oct 2011

EC approves Lilly's ALIMTA as continuation maintenance therapy for NSCLC

Eli Lilly and Company announced today that the European Commission has granted approval for the use of ALIMTA (pemetrexed for injection) as a single agent for continuation maintenance therapy in patients with a particular type of lung cancer, called advanced nonsquamous non-small cell lung cancer

29 Oct 2011

Dietary intervention in adolescence benefits glycemic control and blood pressure long-term

A recent study has found that a childhood behavioral intervention to lower dietary intake of total fat and saturated fat and increase consumption of foods that are good sources of dietary fiber resulted in significantly lower fasting plasma glucose levels and lower systolic blood pressure when study participants were re-evaluated in young adulthood.

28 Oct 2011

Biogen Idec third quarter revenues increase 11% to $1.3 billion

Biogen Idec Inc., a global biotechnology leader in the discovery, development, manufacturing and commercialization of innovative therapies, today announced its third quarter 2011 results.

28 Oct 2011

Reasons for caution about experimental malaria vaccine

Writing in KPLU's "Humanosphere" blog, Tom Paulson responds to last week's announcement of results from an ongoing clinical trial of an experimental malaria vaccine, saying, "Despite the hype and fanfare, many experts at the Seattle meeting said this experimental vaccine actually so far represents only incremental progress -- a scientific achievement which may still turn out to have little practical utility in the real world."

28 Oct 2011

DiaGenic reports operating revenue of NOK 276 thousand for third quarter 2011

DiaGenic has successfully finalized the first clinical study in collaboration with Pfizer, the market leader for Alzheimer's therapeutics sales and Pfizer has confirmed DiaGenic's findings resulting in a press release October 14th.

28 Oct 2011

Clinical Trial News and Research

FDA approves Abbott's XIENCE PRIME Everolimus Eluting Coronary Stent System

Rigel reports net loss of $17.9 million for third quarter 2011

Multi-centre phase II trial for new brain tumor surgical technique starts in the UK

Non-invasive rtACS treatment can reduce partial blindness

Focused training increases physician's ability to find potentially precancerous polyps

Vegenics receives IND approval from FDA for VGX-100 Phase I study in late stage cancers

Positive initial results from CytRx's INNO-206 Phase 1b/2 clinical trial for advanced solid tumors

Fierce Vaccines highlights Inovio's VGX-3100 as one of 10 Promising Therapeutic Vaccines

Hercules Pharma granted rights to license 22nd Century's X-22 smoking cessation aid

Medtronic’s atrial fibrillation device fails to impress safety panel

Ovarian cancer patients with many folate receptors benefit from new therapy

Some experts question early release of RTS,S malaria vaccine trial data

More than 50,000 patients at high risk of SCA have been prescribed ZOLL's LifeVest

FDA approves Medtronic's LGS IDE for clinical trial to treat Type 1 diabetes

Merck third quarter global sales increase 8% to $12.0 billion

EC approves Lilly's ALIMTA as continuation maintenance therapy for NSCLC

Dietary intervention in adolescence benefits glycemic control and blood pressure long-term

Biogen Idec third quarter revenues increase 11% to $1.3 billion

Reasons for caution about experimental malaria vaccine

DiaGenic reports operating revenue of NOK 276 thousand for third quarter 2011

eBook: Using iPSCs models for human disease research and drug discovery eBook

Latest eBooks

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Driving innovation in Korean drug development

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer